Alzamend Neuro Shares Dip With AL001 Trial in Focus, Cash Concerns Linger
Alzamend Neuro shares fell 4 cents to $1.14 Thursday, lagging biotech peers as investors awaited a clinical update and eyed funding concerns. The company reported no revenue and $2.7 million in cash, warning it lacks funds for a full year. Nasdaq notified Alzamend it was out of compliance with listing rules. Topline Phase II data for its lithium candidate in bipolar disorder are expected in Q3 2026.